The $165M im­munol­o­gy start­up Sheila Gu­jrathi bet on af­ter Re­cep­tos, Gos­samer is shoot­ing for an IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Sheila Gu­jrathi has kept her­self busy since leav­ing the helm of Gos­samer Bio in the af­ter­math of a mid-stage flop. She signed on to a few biotech boards, most re­cent­ly to be­come Ven­tyx Bio’s ex­ec­u­tive chair.

But it turns out her con­nec­tion with the biotech runs much deep­er. As Ven­tyx re­vealed in its S-1, Gu­jrathi made a small in­vest­ment in the com­pa­ny dur­ing the Se­ries A — which took place be­tween Feb­ru­ary and June 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.